Intellance-2: omics data on recurrent glioblastoma patients participating in the Intellance-2 clinical trial, prior to treatment.
This study contains omics data from patients from the Intellance-2 clinical trial, in which effectiveness of ABT414 in EGFR amplified recurrent glioblastoma patients was tested. Patients were randomly assigned to one of three arms: (1) standard of care treatement (TMZ or CCNU), (2) Only ABT414 and (3) ABT414 + (TMZ|CCNU)
- Type: Other
- Archiver: European Genome-Phenome Archive (EGA)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Dataset ID | Description | Technology | Samples |
---|---|---|---|
EGAD00001007943 | Illumina NovaSeq 6000 | 224 | |
EGAD00001007944 | NextSeq 500 | 222 | |
EGAD00001007945 | NextSeq 500 | 216 |
Publications | Citations |
---|---|
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.
Neurooncol Adv 2: 2020 vdz051 |
13 |
The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis.
Neuro Oncol 24: 2022 429-441 |
5 |